Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Onesource Specialty Pharma reported robust Q1 FY27 results, with revenue growing 37% YoY to ₹449 crore and EBITDA up 39% YoY to ₹123.3 crore. The strong performance was driven by the commercial launch of semaglutide and new MSA contracts.
Jul 24 2026 21:11:37
Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Change in Management
Onesource Specialty Pharma announced that Ravi Kumar, Global Head – Injectables/Head of Corporate Strategy, Portfolio & SPO, has resigned from his Senior Management Personnel (SMP) position. The resignation is effective July 24, 2026, creating uncertainty in key strategic areas.
Jul 24 2026 19:46:24
Onesource Specialty Pharma Ltd - 544292 - Board Meeting Outcome for Intimation Of The Outcome Of The Board Meeting Dated July 24, 2026, For The Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30, 2026
Onesource Specialty Pharma board approved Q1 FY27 financial results. Standalone total income was ₹450.26 cr and profit after tax was ₹51.23 cr. Consolidated total income stood at ₹452.83 cr and profit after tax at ₹25.00 cr. Subsidiary Biolexis faces $136.32 mn legal claim from Prestige Biopharma, pending arbitration.
Jul 24 2026 18:58:44
Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Onesource Specialty Pharma will host an Earnings Call on July 25, 2026, at 10:00 AM IST. The call aims to discuss the unaudited financial results for Q1 FY27 (quarter ended June 30, 2026).
Jul 21 2026 12:20:53
Onesource Specialty Pharma Ltd - 544292 - Board Meeting Intimation for Approval Of The Unaudited Financial Results For The Quarter Ended June 30, 2026.
Onesource Specialty Pharma Board will convene on July 24, 2026, to approve its Q1 FY27 financial results. The meeting will also address other agenda items.
Jul 20 2026 18:23:22
Onesource Specialty Pharma Ltd - 544292 - Onesource Specialty Pharma And Formycon AG Announce
Strategic Manufacturing Partnership For Biosimilars
Onesource Specialty Pharma entered a strategic manufacturing partnership with Formycon AG for biosimilars. The company will provide Drug Substance and Drug Product manufacturing from its Bangalore facility, supporting Formycon's global biosimilar programs.
Jul 14 2026 10:00:59
Read More